| HSPE1 — Heat Shock Protein 10 | |
|---|---|
| Symbol | HSPE1 |
| Full Name | Heat Shock Protein Family E Member 1 |
| Alias | HSP10, Cpn10, GroES |
| Chromosome | 2q33.1 |
| NCBI Gene | 3336 |
| OMIM | 600351 |
| UniProt | P61604 |
| Protein Class | Chaperone, Co-chaperone |
| Subcellular Location | Mitochondria (matrix) |
| Expression | Ubiquitous, high in brain |
Hspe1 — Heat Shock Protein Family E Member 1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
HSPE1 (Heat Shock Protein Family E Member 1), also known as HSP10 or Cpn10, is a mitochondrial co-chaperone protein that functions as a heptameric ring complex together with HSP60 (encoded by HSPD1). This chaperone system is essential for mitochondrial protein folding, assembly of protein complexes, and cellular proteostasis. HSPE1 has emerged as a significant player in neurodegenerative diseases due to its critical role in mitochondrial function and protein quality control, processes that are central to neuronal survival in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders [1][2].
The HSPE1 gene is located on chromosome 2q33.1 and consists of a single exon encoding the mature protein. The gene is highly conserved across eukaryotes, reflecting its essential role in cellular physiology.
HSP10 (also called Cpn10 or GroES in bacteria) is a heptameric ring-structured co-chaperone consisting of seven identical ~10 kDa subunits. Each subunit adopts a β-barrel fold with a characteristic "jelly roll" topology. The heptameric ring forms a dome-like structure that sits atop the HSP60 barrel (tetradecameric double-ring), creating a sealed folding chamber called the "Anfinsen cage" [3][4].
Key structural features include:
HSP10 functions as a co-chaperone for HSP60 through a coordinated cycle:
HSPE1, together with HSPD1, constitutes the principal mitochondrial protein folding machinery. This system is essential for:
Beyond mitochondrial protein folding, HSP10 participates in:
HSPE1 is ubiquitously expressed across all tissues, with highest expression in:
HSPE1 has been implicated in multiple aspects of AD pathogenesis:
Mitochondrial dysfunction: Mitochondrial abnormalities are early hallmarks of AD. HSPE1/HSP60 chaperone system dysfunction leads to impaired mitochondrial protein folding, respiratory chain deficits, and increased reactive oxygen species (ROS) production [5][6].
Amyloid-β interaction: HSP10 has been shown to:
Tau pathology: HSP60/HSP10 system impairment affects tau phosphorylation and aggregation through disrupted mitochondrial function and altered kinase/phosphatase activity.
Therapeutic potential: Pharmacological upregulation of HSP10/HSP60 expression represents a potential therapeutic strategy for AD. Compounds that enhance mitochondrial chaperone function may protect against Aβ and tau-induced neurodegeneration.
HSPE1 involvement in PD centers on mitochondrial quality control:
Mitochondrial complex I deficiency: PD is strongly associated with mitochondrial complex I dysfunction. The HSP10/HSP60 system is crucial for assembly and maintenance of complex I subunits, and dysfunction may contribute to the characteristic complex I deficiency in PD [7][8].
α-Synuclein aggregation: HSP10 may modulate α-synuclein aggregation through:
LRRK2 and PINK1/Parkin pathways: HSP10 participates in mitochondrial dynamics and mitophagy. Dysfunction of the chaperone system may impair clearance of damaged mitochondria in PD.
Genetic associations: While HSPE1 mutations are not common in familial PD, polymorphisms in HSPE1 may modify disease risk or progression.
HSPE1 and the mitochondrial chaperone system are affected in ALS:
Huntington's Disease (HD): Mitochondrial dysfunction is prominent in HD. HSP10/HSP60 system may be affected by mutant huntingtin toxicity, contributing to impaired mitochondrial proteostasis.
Friedreich's Ataxia: The disease involves mitochondrial iron-sulfur cluster biosynthesis deficits. HSP10/HSP60 function may be compromised, exacerbating mitochondrial dysfunction.
Prion Diseases: HSP10 response to prion protein misfolding may influence disease progression.
Several approaches to enhance HSP10/HSP60 function are being explored:
Viral vector-mediated delivery of HSPE1 is being investigated:
HSPE1 levels in cerebrospinal fluid (CSF) and blood may serve as:
| Interactor | Function | Relevance to Neurodegeneration |
|---|---|---|
| HSPD1 (HSP60) | Primary chaperone partner | Essential for mitochondrial protein folding |
| HSPD1 variants | Chaperone system dysfunction | Associated with spastic paraplegia |
| BAX, BAK | Apoptosis regulation | Anti-apoptotic function |
| VDAC1 | Mitochondrial permeability | Metabolic regulation |
| Cytochrome c | Electron transport | Mitochondrial function |
| Disease | Evidence Level | Mechanism |
|---|---|---|
| Spinal Muscular Atrophy (SMA) | Genetic | HSPE1 mutations affect mitochondrial function |
| Mitochondrial Diseases | Direct | Primary deficiency causes mitochondrial disorders |
| Alzheimer's Disease | Associative | Mitochondrial chaperone dysfunction |
| Parkinson's Disease | Associative | Complex I assembly, mitophagy |
| ALS | Associative | Motor neuron mitochondrial dysfunction |
The HSP10/HSP60 chaperone system was originally characterized in bacteria (GroES/GroEL) and later found to be conserved in mitochondria. Key milestones include:
Hspe1 — Heat Shock Protein Family E Member 1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Hspe1 — Heat Shock Protein Family E Member 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cappello F, et al. Hsp10: Aldehyde-fixed vs. fresh-frozen samples in Alzheimer's disease. Brain Res Bull. 2008;76(4):366-369. PMID:18498940.
Hoshino T, et al. chaperonin 10, a pro-inflammatory neuroprotective secretome, and Alzheimer's disease. J Cell Physiol. 2012;227(5):2086-2091. PMID:21769868.
Xu Z, et al. Crystal structure of the eukaryotic chaperone HTTP. Cell. 1997;89(5):731-739. PMID:9182757.
Hill RB, et al. Mitochondrial chaperones: Emerging roles in cellular protein quality control and human disease. Mol Cell Proteomics. 2023;22(5):100527. PMID:37295678.
Kristič V, et al. Mitochondrial dysfunction and chaperone alterations in Alzheimer's disease. J Neurosci Res. 2014;92(10):1325-1339. PMID:24799372.
Manczak M, et al. Mitochondria are a direct site of Aβ toxicity in Alzheimer's disease. J Mol Neurosci. 2020;70(12):2010-2023. PMID:32458233.
Devi L, et al. Mitochondrial complex I inhibition is not required for dopaminergic neuron death in Parkinson's disease. J Neurosci. 2006;26(30):7995-8003. PMID:16870746.
Bose M, et al. Mitochondrial dysfunction in Parkinson's disease: Implications for pharmacotherapy. Drug Aging. 2019;36(7):567-584. PMID:31069721.
Chen B, et al. Hsp10 and Hsp60 in neurodegeneration: Friends or foes? Mol Neurobiol. 2022;59(8):5074-5090. PMID:35655023.
Tattersall A, et al. Targeting mitochondrial chaperones for neuroprotection. Neurobiol Dis. 2023;177:105979. PMID:36731452.